Terminal / Weight Loss
Survodutide
Phase 3aka BI 456906
Dual GLP-1/glucagon agonist in phase 3 for obesity and fatty liver.
Mechanism
Activates GLP-1 and glucagon receptors: appetite down, energy expenditure up. The glucagon arm is also why it's being pushed hard for MASH, the serious fatty-liver disease.
Regulatory & Safety Status
Investigational (Boehringer Ingelheim and Zealand Pharma). Not approved.
Research
2026Journal of chromatography. A
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application
2026Diabetes therapy : research, treatment and education of diabetes and related disorders
Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)
2026Journal of clinical medicine
Anti-Obesity Medications in Longevity and Aesthetic Medicine
2026Frontiers in endocrinology
Incretin analogues as cardiovascular agents: a state-of-the-art review
2024PubMed
Latest survodutide research